PMID- 34187866
OWN - NLM
STAT- MEDLINE
DCOM- 20220103
LR  - 20220103
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 92
IP  - 12
DP  - 2021 Dec
TI  - GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: 
      diagnostic and prognostic performance.
PG  - 1305-1312
LID - 10.1136/jnnp-2021-326487 [doi]
AB  - BACKGROUND: Frontotemporal lobar degeneration (FTLD) and primary psychiatric 
      disorders (PPD) are characterised by overlapping clinical features but different 
      aetiologies. Here, we assessed for the first time the potential of blood glial 
      fibrillar acidic protein (GFAP), marker of astrogliosis, as a discriminative and 
      prognostic tool in FTLD and PPD. METHODS: The levels of GFAP in serum (sGFAP) of 
      patients with FTLD (N=107) and PPD (N=44) and GFAP in whole blood samples (bGFAP) 
      from FTLD (N=10), PPD (N=10) and healthy controls (N=18) were measured. We 
      evaluated whether the sGFAP levels associate with C9orf72 repeat expansion, 
      survival of FTLD and PPD patients, and brain atrophy assessed cross-sectionally 
      and longitudinally by structural T1W MRI. We also examined the correlation 
      between sGFAP and bGFAP levels in a subset of patients. RESULTS: sGFAP and bGFAP 
      levels were elevated in the FTLD group compared with the PPD or control groups. 
      Receiver operating characteristic analysis indicated an excellent diagnostic 
      performance between FTLD and PPD (the area under the curve (AUC)=0.820, 95% CI 
      0.745 to 0.896). sGFAP and bGFAP levels showed a strong correlation and elevated 
      sGFAP levels significantly associated with atrophy rate in the temporal cortex 
      and predicted shorter survival time in patients with FTLD. No association with 
      C9orf72 repeat expansion was detected. CONCLUSIONS: sGFAP enabled differentiation 
      of patients with FTLD and PPD and associated with shorter survival and more 
      severe brain atrophy rate in patients with FTLD. These results suggest that 
      blood-based GFAP represents a minimally invasive and useful biomarker in the 
      differential diagnostics between patients with FTLD and PPD and in evaluating 
      disease progression and astrogliosis in FTLD.
CI  - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Katisko, Kasper
AU  - Katisko K
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Cajanus, Antti
AU  - Cajanus A
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Huber, Nadine
AU  - Huber N
AD  - A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Jaaskelainen, Olli
AU  - Jaaskelainen O
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Kokkola, Tarja
AU  - Kokkola T
AUID- ORCID: 0000-0002-3303-3912
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Karkkainen, Virve
AU  - Karkkainen V
AD  - Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
FAU - Rostalski, Hannah
AU  - Rostalski H
AD  - A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Hartikainen, Paivi
AU  - Hartikainen P
AD  - Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
FAU - Koivisto, Anne M
AU  - Koivisto AM
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
AD  - Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
AD  - Department of Internal Medicine and Rehabilitation, Geriatrics, Helsinki 
      University Hospital, Helsinki, Finland.
AD  - Department of Neurosciences, University of Helsinki, Helsinki, Finland.
FAU - Hannonen, Sanna
AU  - Hannonen S
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
AD  - Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
FAU - Lehtola, Juha-Matti
AU  - Lehtola JM
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Korhonen, Ville E
AU  - Korhonen VE
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Helisalmi, Seppo
AU  - Helisalmi S
AD  - Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, 
      Kuopio, Finland.
FAU - Koivumaa-Honkanen, Heli
AU  - Koivumaa-Honkanen H
AD  - Institute of Clinical Medicine, Psychiatry, University of Eastern Finland, 
      Kuopio, Finland.
AD  - Mental Health and Wellbeing Center, Kuopio University Hospital, Kuopio, Finland.
FAU - Herukka, Sanna-Kaisa
AU  - Herukka SK
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland.
AD  - Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
FAU - Remes, Anne M
AU  - Remes AM
AD  - Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.
AD  - Medical Research Center, Oulu University Hospital, Oulu, Finland.
FAU - Solje, Eino
AU  - Solje E
AUID- ORCID: 0000-0001-9940-9524
AD  - Institute of Clinical Medicine - Neurology, University of Eastern Finland, 
      Kuopio, Finland eino.solje@uef.fi.
AD  - Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
FAU - Haapasalo, Annakaisa
AU  - Haapasalo A
AD  - A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 
      Kuopio, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210629
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Biomarkers)
RN  - 0 (Glial Fibrillary Acidic Protein)
SB  - IM
CIN - J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1253. PMID: 34479952
MH  - Aged
MH  - Atrophy/blood/diagnostic imaging
MH  - Biomarkers/blood
MH  - Brain/*diagnostic imaging
MH  - Disease Progression
MH  - Female
MH  - Frontotemporal Dementia/blood/*diagnosis/diagnostic imaging
MH  - Glial Fibrillary Acidic Protein/*blood
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Sensitivity and Specificity
MH  - Survival Rate
OTO - NOTNLM
OT  - MRI
OT  - frontotemporal dementia
COIS- Competing interests: None declared.
EDAT- 2021/07/01 06:00
MHDA- 2022/01/04 06:00
CRDT- 2021/06/30 05:51
PHST- 2021/02/25 00:00 [received]
PHST- 2021/06/12 00:00 [accepted]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2022/01/04 06:00 [medline]
PHST- 2021/06/30 05:51 [entrez]
AID - jnnp-2021-326487 [pii]
AID - 10.1136/jnnp-2021-326487 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312. doi: 
      10.1136/jnnp-2021-326487. Epub 2021 Jun 29.